These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

937 related articles for article (PubMed ID: 20451454)

  • 1. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
    Rubnitz JE; Inaba H; Dahl G; Ribeiro RC; Bowman WP; Taub J; Pounds S; Razzouk BI; Lacayo NJ; Cao X; Meshinchi S; Degar B; Airewele G; Raimondi SC; Onciu M; Coustan-Smith E; Downing JR; Leung W; Pui CH; Campana D
    Lancet Oncol; 2010 Jun; 11(6):543-52. PubMed ID: 20451454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
    Döhner H; Weber D; Krzykalla J; Fiedler W; Kühn MWM; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Fransecky L; Koller E; Wulf G; Schleicher J; Ringhoffer M; Greil R; Hertenstein B; Krauter J; Martens UM; Nachbaur D; Samra MA; Machherndl-Spandl S; Basara N; Leis C; Schrade A; Kapp-Schwoerer S; Cocciardi S; Bullinger L; Thol F; Heuser M; Paschka P; Gaidzik VI; Saadati M; Benner A; Schlenk RF; Döhner K; Ganser A;
    Lancet Haematol; 2023 Jul; 10(7):e495-e509. PubMed ID: 37187198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.
    O'Hear C; Inaba H; Pounds S; Shi L; Dahl G; Bowman WP; Taub JW; Pui CH; Ribeiro RC; Coustan-Smith E; Campana D; Rubnitz JE
    Cancer; 2013 Nov; 119(22):4036-43. PubMed ID: 24006085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.
    Cooper TM; Franklin J; Gerbing RB; Alonzo TA; Hurwitz C; Raimondi SC; Hirsch B; Smith FO; Mathew P; Arceci RJ; Feusner J; Iannone R; Lavey RS; Meshinchi S; Gamis A
    Cancer; 2012 Feb; 118(3):761-9. PubMed ID: 21766293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.
    Hills RK; Castaigne S; Appelbaum FR; Delaunay J; Petersdorf S; Othus M; Estey EH; Dombret H; Chevret S; Ifrah N; Cahn JY; Récher C; Chilton L; Moorman AV; Burnett AK
    Lancet Oncol; 2014 Aug; 15(9):986-96. PubMed ID: 25008258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.
    Elsayed AH; Cao X; Mitra AK; Wu H; Raimondi S; Cogle C; Al-Mansour Z; Ribeiro RC; Gamis A; Kolb EA; Aplenc R; Alonzo TA; Meshinchi S; Rubnitz J; Pounds S; Lamba JK
    J Clin Oncol; 2022 Mar; 40(7):772-783. PubMed ID: 34990262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
    Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
    Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
    Castaigne S; Pautas C; Terré C; Raffoux E; Bordessoule D; Bastie JN; Legrand O; Thomas X; Turlure P; Reman O; de Revel T; Gastaud L; de Gunzburg N; Contentin N; Henry E; Marolleau JP; Aljijakli A; Rousselot P; Fenaux P; Preudhomme C; Chevret S; Dombret H;
    Lancet; 2012 Apr; 379(9825):1508-16. PubMed ID: 22482940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
    Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
    Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.
    Burnett AK; Hills RK; Milligan D; Kjeldsen L; Kell J; Russell NH; Yin JA; Hunter A; Goldstone AH; Wheatley K
    J Clin Oncol; 2011 Feb; 29(4):369-77. PubMed ID: 21172891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial.
    Rubnitz JE; Lacayo NJ; Inaba H; Heym K; Ribeiro RC; Taub J; McNeer J; Degar B; Schiff D; Yeoh AE; Coustan-Smith E; Wang L; Triplett B; Raimondi SC; Klco J; Choi J; Pounds S; Pui CH
    J Clin Oncol; 2019 Aug; 37(23):2072-2081. PubMed ID: 31246522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial.
    Stelljes M; Middeke JM; Bug G; Wagner-Drouet EM; Müller LP; Schmid C; Krause SW; Bethge W; Jost E; Platzbecker U; Klein SA; Schubert J; Niederland J; Kaufmann M; Schäfer-Eckart K; Schaich M; Baldauf H; Stölzel F; Petzold C; Röllig C; Alakel N; Steffen B; Hauptrock B; Schliemann C; Sockel K; Lang F; Kriege O; Schaffrath J; Reicherts C; Berdel WE; Serve H; Ehninger G; Schmidt AH; Bornhäuser M; Mikesch JH; Schetelig J;
    Lancet Haematol; 2024 May; 11(5):e324-e335. PubMed ID: 38583455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
    Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
    Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.
    Pilorge S; Rigaudeau S; Rabian F; Sarkozy C; Taksin AL; Farhat H; Merabet F; Ghez S; Raggueneau V; Terré C; Garcia I; Renneville A; Preudhomme C; Castaigne S; Rousselot P
    Am J Hematol; 2014 Apr; 89(4):399-403. PubMed ID: 24375467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.
    Alexander TB; Wang L; Inaba H; Triplett BM; Pounds S; Ribeiro RC; Pui CH; Rubnitz JE
    Cancer; 2017 Oct; 123(19):3791-3798. PubMed ID: 28556917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML.
    Jaramillo S; Krisam J; Le Cornet L; Kratzmann M; Baumann L; Sauer T; Crysandt M; Rank A; Behringer D; Teichmann L; Görner M; Trappe RU; Röllig C; Krause S; Hanoun M; Hopfer O; Held G; Buske S; Fransecky L; Kayser S; Schliemann C; Schaefer-Eckart K; Al-Fareh Y; Schubert J; Geer T; Kaufmann M; Brecht A; Niemann D; Kieser M; Bornhäuser M; Platzbecker U; Serve H; Baldus CD; Müller-Tidow C; Schlenk RF
    Trials; 2021 Nov; 22(1):765. PubMed ID: 34732236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
    Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
    Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.
    Petersdorf SH; Kopecky KJ; Slovak M; Willman C; Nevill T; Brandwein J; Larson RA; Erba HP; Stiff PJ; Stuart RK; Walter RB; Tallman MS; Stenke L; Appelbaum FR
    Blood; 2013 Jun; 121(24):4854-60. PubMed ID: 23591789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
    Freeman SD; Hills RK; Virgo P; Khan N; Couzens S; Dillon R; Gilkes A; Upton L; Nielsen OJ; Cavenagh JD; Jones G; Khwaja A; Cahalin P; Thomas I; Grimwade D; Burnett AK; Russell NH
    J Clin Oncol; 2018 May; 36(15):1486-1497. PubMed ID: 29601212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial.
    Lancet JE; Uy GL; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Faderl S; Cortes JE
    Lancet Haematol; 2021 Jul; 8(7):e481-e491. PubMed ID: 34171279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.